

Press Release

14 June 2016

European public and private organisations are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2)

VAC2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The initiative that started on 1 March 2016 aims to provide the data to support the 'Consistency Approach' for quality control of established vaccines. The current quality control approach for final products relies on *in vivo* methods.

"VAC2VAC takes into account both vaccine safety and animal welfare", says Prof. Coenraad Hendriksen from Intravacc and Utrecht University, one of the key promoters of the project and the approach behind it. "It will allow us to move away from the traditional paradigm of vaccine batch release testing and to accelerate the introduction of a new paradigm based on innovative non-animal techniques".

The industry representatives on the scientific management team, Catrina Stirling from Zoetis, Sylvie Uhlich from Sanofi Pasteur, and Denis Lambrigts from GSK, noted the importance and impact of this project. "The VAC2VAC project provides a unique platform to support the transition away from *in vivo* batch release testing for vaccines. It brings together both the human and veterinary pharmaceutical industry along with academia and regulators, to build a platform for the development, validation and regulatory acceptance of alternative approaches. For industry this is a very positive One Health approach to the challenge of replacement of the long established *in vivo* test methods and all companies involved are committed to the success of this project".

VAC2VAC is a public-private consortium of twenty partners, involving experts from veterinary and human vaccine industry in a partnership with Official Medicines Control Laboratories, academia, translational research organisations, and vaccinology alliances. To achieve their goal, the project partners will develop, optimise and evaluate physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies. The ultimate goal of the project is to develop tests and approaches that will allow acceptance of the Consistency Approach for existing vaccines by the regulatory agencies and thereby significantly reducing in the future the use of animals for batch testing in routine vaccine production.



Facts about VAC2VAC:

Start date: 1 March 2016

End date: 28 February 2021

Total cost: € 15.98 M

IMI contribution: € 7.85 M

Coordinator: Odile Leroy, European Vaccine Initiative (EVI)

Scientific Coordinators: Coenraad Hendriksen, Intravacc; Sylvie Uhlich, Sanofi Pasteur; Catrina Stirling, Zoetis; Denis Lambrigts, GSK.

Partners: A total of 20 partners from seven different countries, plus one international organisation.

Contact:

Dr. Odile Leroy

European Vaccine Initiative (EVI)

Email: contact.us@euvaccine.eu

Phone: +49 6221 565974

Participants

European Vaccine Initiative	Germany
National Institute for Public Health and the Environment	The Netherlands
National Institute for Biological Standards and Control	United Kingdom
Paul-Ehrlich Institute	Germany
European Commission, Joint Research Centre	International
University of Utrecht	The Netherlands
University Medical Center Groningen	The Netherlands
Institute for Translational Vaccinology	The Netherlands
University of Applied Sciences Utrecht	The Netherlands
Istituto Superiore di Sanità	Italy
Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH (Austrian Agency for Health and Food Safety)	Austria
International Alliance for Biological Standardization for Europe	France
Scientific Institute of Public Health	Belgium
Biomedical Primate Research Centre	The Netherlands
Sanofi Pasteur	France
Zoetis	Belgium
Merial	France
Boehringer Ingelheim	Germany
Merck Sharp & Dohme	The Netherlands
GSK	Belgium

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement N° 115924. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA

